United States & Pfizer
28 shared events · Importance 4 · Last updated Aug 17, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
United States: The expanded approval of HYMPAVZI>>> by the United States — Food and Drug Administration>>> directly impacts the healthcare market and patients within the United States>>>.
Pfizer: The expanded approval of HYMPAVZI by the United States — Food and Drug Administration>>> is a significant positive development for Pfizer>>>, enhancing its product portfolio and market reach in the hemophilia treatment space. This approval is expected to boost Pfizer>>>'s revenue and solidify its position as a leader in rare disease therapies.
Jun 08, 2026 · 7 articles
Regulatory
United States: The U.S. is the primary market for the regulatory submission.
Pfizer: Pfizer is the applicant seeking FDA approval for its drug combination; positive regulatory news may support revenue growth.
Jul 22, 2026 · 6 articles
Tech
United States: The United States is the primary market for the Lyme disease vaccine, with a significant and expanding incidence of the disease. Regulatory approval within the United States, particularly from the United States — Food and Drug Administration, is crucial for the vaccine's availability.
Pfizer: Pfizer is a pharmaceutical company developing a new Lyme disease vaccine, which has shown 70-75% effectiveness in late-stage studies. The company plans to seek regulatory approval, which could significantly boost its market position in infectious disease prevention.
Apr 30, 2026 · 24 articles
Regulatory
United States: The U.S. is a key market for the vaccine, with high Lyme disease incidence and a large at-risk population.
Pfizer: Pfizer is the lead developer and would exclusively manufacture and commercialize the vaccine if approved. The EMA validation advances its pipeline and could provide a new revenue stream.
Aug 14, 2026 · 12 articles
Tech
United States: The United States Food and Drug Administration approved the RSVpreF vaccine in 2023, and the United States — Centers for Disease Control and Prevention provides statistics on RSV hospitalizations, highlighting the public health relevance of the vaccine within the nation.
Pfizer: Pfizer manufactures the RSVpreF vaccine, which has shown significant effectiveness in preventing RSV-associated hospitalizations in infants. This positive real-world data validates their product and could lead to increased sales and market share in the vaccine segment.
Jun 05, 2026 · 7 articles
Business
United States: The US stands to gain from increased investment and manufacturing, aligning with the Trump administration's priorities. The deal would likely require US regulatory approval.
Pfizer: Pfizer is referenced as a historical comparator, having attempted a hostile takeover of AstraZeneca in 2014. The current talks evoke memories of that failed bid.
Aug 02, 2026 · 60 articles
Regulatory
United States: The U.S. gains a new flu vaccine option, potentially improving public health outcomes for older adults.
Pfizer: Pfizer, a rival in mRNA vaccines, may face competitive pressure as Moderna expands its mRNA platform into flu.
Aug 05, 2026 · 105 articles
Business
United States: Engaged in conflict with Iran, impacting oil prices and markets. Also intervened in yen markets.
Pfizer: Reported upbeat quarterly results, leading to a stock gain.
Jul 14, 2026 · 280 articles
Regulatory
United States: The U.S. is the primary location of the data center boom and the legal framework governing eminent domain.
Pfizer: Pfizer facility was the intended beneficiary of the Kelo seizure, but the company later left New London.
Jul 16, 2026 · 6 articles
Domestic
United States: The US has shifted toward a risk-based approach; Health Secretary Robert F. Kennedy Jr. has advocated stopping recommendations for children.
Pfizer: Pfizer's COVID-19 vaccine (with BioNTech) may see reduced demand in Germany; the company has faced scrutiny over adverse event data.
Jul 13, 2026 · 6 articles
International
United States: Accounts for 75% of computing power among top 500 AI supercomputers; home to many tech companies on the commission.
Pfizer: CEO Albert Bourla joined the AI for Good Global Commission.
Apr 20, 2026 · 123 articles
Accidents
United States: The United States>>> has repatriated its citizens from the MV Hondius and is monitoring them, with some placed under quarantine orders, demonstrating its efforts to manage potential imported cases.
Pfizer: Pfizer is mentioned in false conspiracy theories linking its vaccine to the Hantavirus outbreak, which health officials are working to counter.
May 07, 2026 · 368 articles
Domestic
United States: The United States is the setting for this event, with its federal health agencies and medical organizations involved in the vaccine recommendation dispute.
Pfizer: Pfizer's Abrysvo is mentioned as the only approved RSV vaccine for use in pregnancy, indicating its market position in this specific vaccine category.
Jun 10, 2026 · 6 articles
Tech
United States: The US is the primary market for the treatment, with regulatory approval and healthcare system implications.
Pfizer: Pfizer's COVID vaccine used BioNTech's mRNA technology, and the success of mRNA cancer vaccines could have indirect implications.
Aug 19, 2026 · 108 articles
Tech
United States: The study population is U.S.-based, and findings may influence public health recommendations.
Pfizer: Andrew T. Chan served as a consultant; no direct impact.
Aug 17, 2026 · 20 articles
Tech
United States: The United States>>> is a key market for prostate cancer treatment, with a significant number of high-risk patients who could benefit from Apalutamide>>>.
Pfizer: Pfizer>>> is mentioned as a competitor with its ARPI drug Xtandi, indicating potential market competition with Johnson & Johnson>>>'s Apalutamide>>>.
May 31, 2026 · 6 articles
Business
United States: Clinical trial sites in the US are part of the study, but no direct impact on the country.
Pfizer: Pfizer has a non-exclusive license to Serina's POZ technology for LNP delivery, but this event does not directly affect Pfizer.
Jul 09, 2026 · 6 articles
Business
United States: Country where Palsonify is approved and where most patients reside.
Pfizer: Competitor in acromegaly market; PALSONIFY may compete with its treatments.
Jul 06, 2026 · 34 articles
Business
United States: Ascentage Pharma has a U.S. presence and FDA clearances, but this event does not directly impact the country.
Pfizer: Pfizer is a partner of Ascentage Pharma, but this event does not directly involve Pfizer.
Jul 26, 2026 · 6 articles
Regulatory
Pfizer: Pfizer previously agreed to lower the cost of prescription drugs for United States — Medicaid following an executive order, setting a precedent for the current deal with Eli Lilly and Company and Novo Nordisk.
Nov 06, 2025 · 6 articles
Regulatory
Pfizer: Pfizer had previously struck a deal with the administration to rein in prices and expects United States — Medicaid discounts to result in price and margin compression next year.
Dec 19, 2025 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States and Pfizer interact across events, view sentiment trends, and discover connected entities.
Open Dashboard